Miniature mass spectrometer-based point-of-care assay for cabotegravir and rilpivirine in whole blood.

ABSTRACT: HIV prevention and treatment with injectable cabotegravir and/or rilpivirine administered once every 4 to 8 weeks is an attractive alternative to daily therapy. Prescribed dosage and drug concentrations in plasma are based on patient data collected in clinical trials, but actual patients are expected to exhibit more variability in drug concentrations, which is important to quantify. Here, we demonstrate the first quantitative point-of-care assay with a miniature mass spectrometer to assess these drug concentrations in whole blood. Quantitative performance is obtained using paper spray ionization in combination with tandem mass spectrometry (MS/MS) in the clinically relevant concentration range of both drugs. Limits of quantitation (LoQs) of cabotegravir and rilpivirine are measured to be 7

SUBMITTER: Pandey S 

PROVIDER: S-EPMC9018536 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature